Innate Pharma: positive data in mycosis fungoides
Treatment with lacutamab showed clinically significant antitumor activity in heavily pretreated patients, independent of KIR3DL2 expression level, and with a safety profile similar to that previously observed.
"These results are very promising and support the continued development of lacutamab to bring better treatments to patients with cutaneous T-cell lymphomas", comments Medical Director Sonia Quaratino.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction